Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SM8S
|
|||
| Former ID |
DNCL002030
|
|||
| Drug Name |
Lebrikizumab
|
|||
| Synonyms |
RG3637
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Severe asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 3 | [1], [2] | |
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [3] | ||
| Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [4], [5], [6], [7] | ||
| Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [8] | ||
| Company |
Aerovance
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-13 (IL13) | Target Info | Modulator | [9] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Fc epsilon RI signaling pathway | ||||
| Measles | ||||
| Asthma | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| TSLP Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | |||
| IL12 signaling mediated by STAT4 | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cytokines and Inflammatory Response | ||||
| Allograft Rejection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7684). | |||
| REF 2 | ClinicalTrials.gov (NCT01875003) A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT00971035) A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids | |||
| REF 5 | ClinicalTrials.gov (NCT00930163) A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids | |||
| REF 6 | ClinicalTrials.gov (NCT01987492) A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma | |||
| REF 7 | ClinicalTrials.gov (NCT02546700) A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | |||
| REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 9 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.